A pharmaceutical composition includes a peptide nucleotide composition including Peptide A and Peptide B. Peptide A may be characterized by having SEQ. ID NO: 1. Peptide A may also be characterized by including 31 amino acids lacking any cysteine-cysteine cross links and including six spaced-out proline residues and four glutamine residues. Peptide B may be characterized by having SEQ. ID NO: 2. Peptide B may also be characterized by including 21 amino acids attached at a seine residue in position 18 to a diadenine (3′-5′) diribonecleotide through a diphosphodiester linkage at the 3′-position.
